Early therapeutic efficacy of condoliase chemonucleolysis for lumbar disc herniation

J Orthop Surg Res. 2024 Dec 30;19(1):890. doi: 10.1186/s13018-024-05405-4.

Abstract

Background: Low back pain is often caused by lumbar disc herniation (LDH). Treatment of LDH is possible using chemonucleolysis of the nucleus pulposus with condoliase injection. However, onset of the therapeutic effect varies among patients, with improvement from an early stage to 3 months post-injection. This study was performed to identify the characteristics of early responders to condoliase therapy.

Methods: A retrospective cohort study was performed in 371 consecutive patients (259 males, 112 females; age, 49.9 ± 18.7 years; follow-up period, 13.1 ± 7.4 months) treated with condoliase injection for LDH between August 2018 and January 2024. Chemonucleolysis was performed with 1 mL of condoliase (1.25 U/mL) injected into the intervertebral nucleus pulposus. Clinical assessments were made before injection and 1 day, and 1, 4 and 12 weeks post-injection. Pain was measured on a visual analogue scale. Herniation parameters were evaluated on axial MRI. The herniated disc volume was measured on plain lumbar radiography. Demographic and clinical data were taken from medical charts. Multivariate logistic regression analysis was used to identify factors with independent relationships with treatment efficacy.

Results: Improvement of leg pain from baseline by ≥ 50% occurred in 21% of cases within one day after condoliase treatment. Patients with this improvement at 1 week post-injection were defined as early responders (n = 142, 38.3%). In multivariate analysis, age < 40 years (p = 0.022, odds ratio (OR): 1.71, 95% confidence interval (CI): 1.12-4.35), Pfirrmann Grade II or III at baseline (p = 0.032, OR: 1.86, 95% CI: 1.17-5.41), and a high intensity MRI signal in the herniation (p = 0.041, OR: 1.87, 95% CI: 1.06-5.27) were significantly associated with early improvement. No patients had anaphylactic shock or neurologic sequelae.

Conclusions: This study confirms the safety and efficacy of chemonucleolysis with condoliase for treating patients with painful LDH. Age, high-intensity MRI signals, and baseline Pfirrmann grade were significant factors associated with early improvement.

Keywords: Chemonucleolysis; Condoliase; Early therapeutic efficacy; Leg pain; Low back pain; Lumbar disc herniation.

MeSH terms

  • Adult
  • Aged
  • Chymopapain / administration & dosage
  • Chymopapain / therapeutic use
  • Cohort Studies
  • Female
  • Follow-Up Studies
  • Humans
  • Intervertebral Disc Chemolysis* / methods
  • Intervertebral Disc Displacement* / diagnostic imaging
  • Intervertebral Disc Displacement* / drug therapy
  • Low Back Pain / drug therapy
  • Low Back Pain / etiology
  • Lumbar Vertebrae* / diagnostic imaging
  • Male
  • Middle Aged
  • Nucleus Pulposus / diagnostic imaging
  • Retrospective Studies
  • Time Factors
  • Treatment Outcome

Substances

  • Chymopapain